Bladder cancer is a common cancer that starts in the bladder lining and is usually detected when patients notice blood in the urine or urinary changes. Most bladder cancers are a type called urothelial cancer, but there are several less common histologic subtypes, called variants. Some examples are squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcomatoid.
In the United States, bladder cancer is the fifth most common cancer, with men being affected about four times more often than women. Globally, bladder cancer is the ninth most common type, with over 600,000 new cases diagnosed each year. Early diagnosis and treatment can improve outcomes for most patients.
The extent of the cancer — how far it has spread — matters, too. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into the bladder muscle wall (muscle-invasive) or if it has spread to distant parts of your body (metastatic).
When your Fred Hutch Cancer Center team designs your treatment plan, they will consider the type and stage of your cancer along with many other factors. The stage is an important part of choosing which treatments are right for you.
Bladder Cancer Care Tailored to You
You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical trials and supportive care services.
Urothelial carcinoma, also known as transitional cell carcinoma (TCC), starts in the urothelial cells that line the inside of the bladder. This is the most common type of bladder cancer. Other types of cancer can start in the bladder, but these are all much less common than urothelial (transitional cell) cancer. At Fred Hutch, our bladder cancer care team treats all types of disease.
Urothelial Carcinoma (Transitional Cell Carcinoma)
If you’re told you have bladder cancer, it's very likely to be a urothelial carcinoma.
Urothelial cells also line the inside of other parts of the urinary tract, such as the part of the kidney that connects to the ureter (called the renal pelvis), the ureters and the urethra.
There are different subtypes of urothelial carcinoma. Most often the subtype doesn’t affect how the cancer is treated, although some subtypes might be more likely to have gene changes that could affect treatment options.
Urothelial Carcinoma with Divergent Differentiation
Sometimes urothelial cancers contain very small areas that look like other cancer types. This is known as divergent differentiation. For example, the cancer may contain areas of squamous or glandular differentiation. Most often, this doesn’t affect treatment.
Other Cancers that Start in the Bladder
Other types can start in the bladder, but these are all much less common than urothelial (transitional cell) cancer. These include squamous cell carcinoma (only 3% to 5% of cases), adenocarcinoma (only 1% to 2%), small cell carcinoma (less than 1%) and sarcoma (very rare).
When physicians and scientists talk about cancer-specific survival rates, they typically mean the percentage of people expected to survive their cancer for at least five years after being diagnosed. (The rate doesn’t include the risk of dying during that time for some other reason.) Overall, the relative five-year survival rate for bladder cancer in the U.S. can vary significantly depending on the stage, extent and other features of the cancer, as well as the general health of the individual and their other medical conditions.
This rate comes from looking at a large group of people. The chance of surviving cancer at least five years can vary greatly from one person to another. Your Fred Hutch care team can explain how statistics like survival rates might apply to you.